These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 1078825)

  • 1. Complement fixation by rheumatoid factor.
    Tanimoto K; Cooper NR; Johnson JS; Vaughan JH
    J Clin Invest; 1975 Mar; 55(3):437-45. PubMed ID: 1078825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of complement fixation by rheumatoid factor using a haemolytic assay system.
    Taylor-Upsahl MM; Johnson PM; Mellbye OJ; Natvig JB
    Clin Exp Immunol; 1977 May; 28(2):204-11. PubMed ID: 872448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rheumatoid factor on complement-mediated phagocytosis.
    McDuffie FC; Brumfield HW
    J Clin Invest; 1972 Dec; 51(12):3007-14. PubMed ID: 4640945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.
    Schreiber AD; Frank MM
    J Clin Invest; 1972 Mar; 51(3):583-9. PubMed ID: 4622104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester.
    Ramsland PA; Movafagh BF; Reichlin M; Edmundson AB
    J Mol Recognit; 1999; 12(4):249-57. PubMed ID: 10440996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement fixation by a two-component antibody system: immunoglobulin G and immunoglobulin M anti-globulin (rheumatoid factor). Parodoxical effect related to immunoglobulin G concentration.
    Schmid FR; Roitt IM; Rocha MJ
    J Exp Med; 1970 Oct; 132(4):673-93. PubMed ID: 5508376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester.
    Ramsland PA; Movafagh BF; Reichlin M; Edmundson AB
    J Mol Recognit; 1999; 12(5):249-57. PubMed ID: 10777254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation by 19S IgM rheumatoid factor: relationship to disease activity in rheumatoid arthritis.
    Robbins DL; Fiegal DW; Leek JC; Shapiro R; Wiesner K
    J Rheumatol; 1986 Feb; 13(1):33-8. PubMed ID: 3701741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A monoclonal anti-idiotype specific for human polyclonal IgM rheumatoid factor.
    Davidson A; Lopez J; Sun D; Prus D
    J Immunol; 1992 Jun; 148(12):3873-8. PubMed ID: 1376343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic measurement of the interaction of rheumatoid factor with IgG-coated latex particles and the influence of the first component of human complement.
    Hällgren R
    Clin Exp Immunol; 1980 Jan; 39(1):154-63. PubMed ID: 6771071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic specificities of human monoclonal and polyclonal IgM rheumatoid factors. The C gamma 2-C gamma 3 interface region contains the major determinants.
    Sasso EH; Barber CV; Nardella FA; Yount WJ; Mannik M
    J Immunol; 1988 May; 140(9):3098-107. PubMed ID: 2452199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryoimmunoglobulinemia in rheumatoid arthritis. Significance in serum of patients with rheumatoid vasculitis.
    Weisman M; Zvaifler N
    J Clin Invest; 1975 Sep; 56(3):725-39. PubMed ID: 169295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally occurring low molecular weight IgM in patients with rheumatoid arthritis, systemic lupus erythematosus and macroglobulinemia. I. Purification and immunologic studies.
    Harisdangkul V; McDougal JS; Knapp M; Christian CL
    J Immunol; 1975 Jul; 115(1):216-22. PubMed ID: 807624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The internal image of IgG in cross-reactive anti-idiotypic antibodies against human rheumatoid factors.
    Fong S; Gilbertson TA; Carson DA
    J Immunol; 1983 Aug; 131(2):719-24. PubMed ID: 6863929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of Clq binding activity by IgM rheumatoid factor.
    Zilberfarb JL; Andrews BS; Young AC; Davis JS
    J Rheumatol; 1985 Jun; 12(3):444-8. PubMed ID: 3876433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.
    Doekes G; Schouten J; Cats A; Daha MR
    Immunology; 1985 Jul; 55(3):555-64. PubMed ID: 4018839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A highly conserved determinant on human rheumatoid factor idiotypes defined by a mouse monoclonal antibody.
    Pasquali JL; Urlacher A; Storck D
    Eur J Immunol; 1983 Mar; 13(3):197-201. PubMed ID: 6187582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles of IgG, IgM rheumatoid factor, and their complexes in the induction of polymorphonuclear leukocyte chemotactic factor from complement.
    Wagner T; Abraham G; Baum J
    J Clin Invest; 1974 Jun; 53(6):1503-11. PubMed ID: 4133792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IgG and IgM rheumatoid factors and complement activation in extraarticular rheumatoid disease.
    Jakle C; Feigal DW; Robbins DL; Shapiro R; Wiesner K
    J Rheumatol; 1985 Apr; 12(2):227-32. PubMed ID: 3875718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.